Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity

Danuglipron demonstrated mean placebo-adjusted weight reductions ranging from -8% to -13% at 32 weeks and -5% to -9.5% at 26 weeks While most common adverse events were mild and gastrointestinal in nature consistent with the mechanism, high rates...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials